JP2005533824A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2005533824A5 JP2005533824A5 JP2004518041A JP2004518041A JP2005533824A5 JP 2005533824 A5 JP2005533824 A5 JP 2005533824A5 JP 2004518041 A JP2004518041 A JP 2004518041A JP 2004518041 A JP2004518041 A JP 2004518041A JP 2005533824 A5 JP2005533824 A5 JP 2005533824A5
- Authority
- JP
- Japan
- Prior art keywords
- interferon
- compound
- pharmaceutical composition
- pharmaceutically acceptable
- composition according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 150000001875 compounds Chemical class 0.000 claims 53
- 239000008194 pharmaceutical composition Substances 0.000 claims 34
- 108010050904 Interferons Proteins 0.000 claims 28
- 102000014150 Interferons Human genes 0.000 claims 28
- 229940079322 interferon Drugs 0.000 claims 28
- 150000003839 salts Chemical class 0.000 claims 24
- 239000011780 sodium chloride Substances 0.000 claims 24
- 239000003443 antiviral agent Substances 0.000 claims 20
- 239000003937 drug carrier Substances 0.000 claims 12
- 239000003112 inhibitor Substances 0.000 claims 12
- 230000002401 inhibitory effect Effects 0.000 claims 12
- CPELXLSAUQHCOX-UHFFFAOYSA-N hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 claims 11
- NBIIXXVUZAFLBC-UHFFFAOYSA-K [O-]P([O-])([O-])=O Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 claims 9
- 239000010452 phosphate Substances 0.000 claims 9
- 239000000137 peptide hydrolase inhibitor Substances 0.000 claims 8
- HVYWMOMLDIMFJA-DPAQBDIFSA-N (3β)-Cholest-5-en-3-ol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 claims 6
- 239000000203 mixture Substances 0.000 claims 6
- NBIIXXVUZAFLBC-UHFFFAOYSA-N phosphoric acid Chemical group OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 claims 6
- 239000000651 prodrug Substances 0.000 claims 6
- 229940002612 prodrugs Drugs 0.000 claims 6
- VEXZGXHMUGYJMC-UHFFFAOYSA-N HCl Chemical group Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims 5
- 241000700605 Viruses Species 0.000 claims 5
- -1 albferon Proteins 0.000 claims 5
- KPGXRSRHYNQIFN-UHFFFAOYSA-L 2-oxoglutarate(2-) Chemical compound [O-]C(=O)CCC(=O)C([O-])=O KPGXRSRHYNQIFN-UHFFFAOYSA-L 0.000 claims 4
- KRKNYBCHXYNGOX-UHFFFAOYSA-K 2qpq Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 claims 4
- YYVYAPXYZVYDHN-UHFFFAOYSA-N 9,10-phenanthroquinone Chemical compound C1=CC=C2C(=O)C(=O)C3=CC=CC=C3C2=C1 YYVYAPXYZVYDHN-UHFFFAOYSA-N 0.000 claims 4
- 101710036216 ATEG_03556 Proteins 0.000 claims 4
- 229940072107 Ascorbate Drugs 0.000 claims 4
- ZVSKZLHKADLHSD-UHFFFAOYSA-N Benzanilide Chemical compound C=1C=CC=CC=1C(=O)NC1=CC=CC=C1 ZVSKZLHKADLHSD-UHFFFAOYSA-N 0.000 claims 4
- 229940050390 Benzoate Drugs 0.000 claims 4
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 claims 4
- GVEZIHKRYBHEFX-NQQPLRFYSA-N CERULENIN Chemical compound C\C=C\C\C=C\CCC(=O)[C@H]1O[C@H]1C(N)=O GVEZIHKRYBHEFX-NQQPLRFYSA-N 0.000 claims 4
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate dianion Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 claims 4
- 102000005927 Cysteine Proteases Human genes 0.000 claims 4
- 108010005843 Cysteine Proteases Proteins 0.000 claims 4
- FIVPIPIDMRVLAY-RBJBARPLSA-N Gliotoxin Chemical compound C1C2=CC=C[C@H](O)[C@H]2N2[C@]1(SS1)C(=O)N(C)[C@@]1(CO)C2=O FIVPIPIDMRVLAY-RBJBARPLSA-N 0.000 claims 4
- 229940103893 Gliotoxin Drugs 0.000 claims 4
- 102100008763 IFNA2 Human genes 0.000 claims 4
- 101700023446 IFNT Proteins 0.000 claims 4
- 108010078049 Interferon alpha-2 Proteins 0.000 claims 4
- 229960004461 Interferon beta-1a Drugs 0.000 claims 4
- 108010005716 Interferon beta-1a Proteins 0.000 claims 4
- 229940028862 Interferon gamma-1b Drugs 0.000 claims 4
- 102000006992 Interferon-alpha Human genes 0.000 claims 4
- 108010047761 Interferon-alpha Proteins 0.000 claims 4
- 108010074328 Interferon-gamma Proteins 0.000 claims 4
- 102000008070 Interferon-gamma Human genes 0.000 claims 4
- 102000015696 Interleukins Human genes 0.000 claims 4
- 108010063738 Interleukins Proteins 0.000 claims 4
- TYQCGQRIZGCHNB-JLAZNSOCSA-N L-ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(O)=C(O)C1=O TYQCGQRIZGCHNB-JLAZNSOCSA-N 0.000 claims 4
- FEWJPZIEWOKRBE-XIXRPRMCSA-N Mesotartaric acid Chemical compound OC(=O)[C@@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-XIXRPRMCSA-N 0.000 claims 4
- 101710003000 ORF1/ORF2 Proteins 0.000 claims 4
- 101700030467 Pol Proteins 0.000 claims 4
- 229940076788 Pyruvate Drugs 0.000 claims 4
- IWUCXVSUMQZMFG-AFCXAGJDSA-N Ribavirin Chemical compound N1=C(C(=O)N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 IWUCXVSUMQZMFG-AFCXAGJDSA-N 0.000 claims 4
- 229960000329 Ribavirin Drugs 0.000 claims 4
- LSNNMFCWUKXFEE-UHFFFAOYSA-L Sulphite Chemical compound [O-]S([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-L 0.000 claims 4
- OGYGFUAIIOPWQD-UHFFFAOYSA-N Thiazolidine Chemical compound C1CSCN1 OGYGFUAIIOPWQD-UHFFFAOYSA-N 0.000 claims 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-M acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 claims 4
- 230000000692 anti-sense Effects 0.000 claims 4
- 235000010323 ascorbic acid Nutrition 0.000 claims 4
- 239000011668 ascorbic acid Substances 0.000 claims 4
- WPYMKLBDIGXBTP-UHFFFAOYSA-M benzoate Chemical compound [O-]C(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-M 0.000 claims 4
- 239000002775 capsule Substances 0.000 claims 4
- 229950005984 cerulenin Drugs 0.000 claims 4
- 230000001419 dependent Effects 0.000 claims 4
- VZCYOOQTPOCHFL-UHFFFAOYSA-N fumaric acid Chemical compound OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 claims 4
- AEMRFAOFKBGASW-UHFFFAOYSA-M glycolate Chemical compound OCC([O-])=O AEMRFAOFKBGASW-UHFFFAOYSA-M 0.000 claims 4
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 claims 4
- 229960003130 interferon gamma Drugs 0.000 claims 4
- 108010042414 interferon gamma-1b Proteins 0.000 claims 4
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 claims 4
- VZCYOOQTPOCHFL-UPHRSURJSA-L maleate(2-) Chemical compound [O-]C(=O)\C=C/C([O-])=O VZCYOOQTPOCHFL-UPHRSURJSA-L 0.000 claims 4
- AFVFQIVMOAPDHO-UHFFFAOYSA-M methanesulfonate Chemical compound CS([O-])(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-M 0.000 claims 4
- BDAGIHXWWSANSR-UHFFFAOYSA-M methanoate Chemical compound [O-]C=O BDAGIHXWWSANSR-UHFFFAOYSA-M 0.000 claims 4
- NHNBFGGVMKEFGY-UHFFFAOYSA-N nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 claims 4
- 125000003729 nucleotide group Chemical group 0.000 claims 4
- MUBZPKHOEPUJKR-UHFFFAOYSA-L oxalate Chemical compound [O-]C(=O)C([O-])=O MUBZPKHOEPUJKR-UHFFFAOYSA-L 0.000 claims 4
- OFOBLEOULBTSOW-UHFFFAOYSA-L propanedioate Chemical compound [O-]C(=O)CC([O-])=O OFOBLEOULBTSOW-UHFFFAOYSA-L 0.000 claims 4
- XBDQKXXYIPTUBI-UHFFFAOYSA-M propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 claims 4
- LCTONWCANYUPML-UHFFFAOYSA-M pyruvate Chemical compound CC(=O)C([O-])=O LCTONWCANYUPML-UHFFFAOYSA-M 0.000 claims 4
- 101710004466 rgy Proteins 0.000 claims 4
- 101710030364 rgy1 Proteins 0.000 claims 4
- 101710030359 rgy2 Proteins 0.000 claims 4
- 229920002033 ribozyme Polymers 0.000 claims 4
- YGSDEFSMJLZEOE-UHFFFAOYSA-M salicylate Chemical compound OC1=CC=CC=C1C([O-])=O YGSDEFSMJLZEOE-UHFFFAOYSA-M 0.000 claims 4
- 229960001860 salicylate Drugs 0.000 claims 4
- AWUCVROLDVIAJX-GSVOUGTGSA-N sn-glycerol 3-phosphate Chemical compound OC[C@@H](O)COP(O)(O)=O AWUCVROLDVIAJX-GSVOUGTGSA-N 0.000 claims 4
- 229940086735 succinate Drugs 0.000 claims 4
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 claims 4
- QAOWNCQODCNURD-UHFFFAOYSA-L sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 claims 4
- 229940095064 tartrate Drugs 0.000 claims 4
- 150000003548 thiazolidines Chemical class 0.000 claims 4
- RYYWUUFWQRZTIU-UHFFFAOYSA-K thiophosphate Chemical compound [O-]P([O-])([O-])=S RYYWUUFWQRZTIU-UHFFFAOYSA-K 0.000 claims 4
- JOXIMZWYDAKGHI-UHFFFAOYSA-M toluene-4-sulfonate Chemical compound CC1=CC=C(S([O-])(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-M 0.000 claims 4
- 229940107161 Cholesterol Drugs 0.000 claims 3
- 241000710831 Flavivirus Species 0.000 claims 3
- 241000710778 Pestivirus Species 0.000 claims 3
- 125000002252 acyl group Chemical group 0.000 claims 3
- 125000000217 alkyl group Chemical group 0.000 claims 3
- 125000004390 alkyl sulfonyl group Chemical group 0.000 claims 3
- 229910000147 aluminium phosphate Inorganic materials 0.000 claims 3
- 235000001014 amino acid Nutrition 0.000 claims 3
- 150000001413 amino acids Chemical class 0.000 claims 3
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims 3
- 150000001720 carbohydrates Chemical class 0.000 claims 3
- 235000014633 carbohydrates Nutrition 0.000 claims 3
- 235000012000 cholesterol Nutrition 0.000 claims 3
- 239000003085 diluting agent Substances 0.000 claims 3
- 239000003814 drug Substances 0.000 claims 3
- 150000002632 lipids Chemical class 0.000 claims 3
- 125000004170 methylsulfonyl group Chemical group [H]C([H])([H])S(*)(=O)=O 0.000 claims 3
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 3
- 241000710781 Flaviviridae Species 0.000 claims 2
- 125000005140 aralkylsulfonyl group Chemical group 0.000 claims 2
- 150000003459 sulfonic acid esters Chemical class 0.000 claims 2
- 208000004576 Flaviviridae Infections Diseases 0.000 claims 1
- 241000711549 Hepacivirus C Species 0.000 claims 1
- 108010012057 RNA Replicase Proteins 0.000 claims 1
- 239000002253 acid Substances 0.000 claims 1
- 229910052739 hydrogen Inorganic materials 0.000 claims 1
- 239000001257 hydrogen Substances 0.000 claims 1
- 125000004435 hydrogen atoms Chemical group [H]* 0.000 claims 1
- 238000001990 intravenous administration Methods 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- OAICVXFJPJFONN-UHFFFAOYSA-N phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 claims 1
- 229910052698 phosphorus Inorganic materials 0.000 claims 1
- 239000011574 phosphorus Substances 0.000 claims 1
- 102000004196 processed proteins & peptides Human genes 0.000 claims 1
- 108090000765 processed proteins & peptides Proteins 0.000 claims 1
Claims (82)
- 医薬的に許容可能な塩が塩酸塩である請求項1に記載の化合物。
- 医薬的に許容可能な塩が塩酸塩である請求項4に記載の医薬組成物。
- 医薬的に許容可能な塩が二塩酸塩である請求項4に記載の医薬組成物。
- 医薬的に許容可能なキャリヤーが経口送達に適している請求項4に記載の医薬組成物。
- 更に第2の抗ウイルス剤を含む請求項4に記載の医薬組成物。
- 第2の抗ウイルス剤がインターフェロン、リバビリン、インターロイキン、NS3プロテアーゼ阻害剤、システインプロテアーゼ阻害剤、フェナントレンキノン、チアゾリジン誘導体、チアゾリジン、ベンズアニリド、ヘリカーゼ阻害剤、ポリメラーゼ阻害剤、ヌクレオチド類似体、グリオトキシン、セルレニン、アンチセンスホスホロチオエートオリゴデオキシヌクレオチド、IRES依存的翻訳の阻害剤、及びリボザイムから構成される群から選択される請求項8に記載の医薬組成物。
- 第2の抗ウイルス剤がインターフェロンである請求項8に記載の医薬組成物。
- 第2の抗ウイルス剤がペグ化インターフェロンα2a、インターフェロンαcon−1、天然インターフェロン、アルブフェロン、インターフェロンβ−1a、ωインターフェロン、インターフェロンα、インターフェロンγ、インターフェロンτ、インターフェロンδ及びインターフェロンγ−1bから構成される群から選択される請求項8に記載の医薬組成物。
- 第2の抗ウイルス剤がインターフェロンα2である請求項8に記載の医薬組成物。
- 化合物が用量単位の形態である請求項4に記載の医薬組成物。
- 用量単位が .01〜50mgの化合物を含有する請求項13に記載の組成物。
- 前記用量単位が錠剤又はカプセル剤である請求項13に記載の組成物。
- 化合物が実質的に純粋形態である請求項4に記載の組成物。
- 化合物の少なくとも90重量%がβ−D異性体である請求項1から3のいずれか一項に記載の化合物。
- 化合物の少なくとも95重量%がβ−D異性体である請求項1から3のいずれか一項に記載の化合物。
- 医薬的に許容可能な塩が塩酸塩である請求項19に記載の医薬組成物。
- 医薬的に許容可能な塩が二塩酸塩である請求項19に記載の医薬組成物。
- 更に化合物を医薬的に許容可能なキャリヤー、希釈剤又は賦形剤中に担持して含む請求項19に記載の医薬組成物。
- 化合物を第2の抗ウイルス剤と併用又は交互投与する請求項19に記載の医薬組成物。
- 第2の抗ウイルス剤がインターフェロン、リバビリン、インターロイキン、NS3プロテアーゼ阻害剤、システインプロテアーゼ阻害剤、チアゾリジン誘導体、チアゾリジン、ベンズアニリド、フェナントレンキノン、ヘリカーゼ阻害剤、ポリメラーゼ阻害剤、ヌクレオチド類似体、グリオトキシン、セルレニン、アンチセンスホスホロチオエートオリゴデオキシヌクレオチド、IRES依存的翻訳の阻害剤、及びリボザイムから構成される群から選択される請求項23に記載の医薬組成物。
- 第2の抗ウイルス剤がインターフェロンである請求項23に記載の医薬組成物。
- 第2の抗ウイルス剤がペグ化インターフェロンα2a、インターフェロンαcon−1、天然インターフェロン、アルブフェロン、インターフェロンβ−1a、ωインターフェロン、インターフェロンα、インターフェロンγ、インターフェロンτ、インターフェロンδ及びインターフェロンγ−1bから構成される群から選択される請求項19に記載の医薬組成物。
- 第2の抗ウイルス剤がインターフェロンα2である請求項26に記載の医薬組成物。
- 宿主がヒトである請求項19に記載の医薬組成物。
- 化合物が用量単位の形態である請求項19に記載の医薬組成物。
- 用量単位が10〜500mgの化合物を含有する請求項29に記載の医薬組成物。
- 前記用量単位が錠剤又はカプセル剤である請求項29に記載の医薬組成物。
- 医薬的に許容可能なキャリヤーが経口又は静脈内送達に適している請求項19に記載の医薬組成物。
- 化合物を実質的に純粋形態で投与する請求項19に記載の医薬組成物。
- 化合物の少なくとも90重量%がβ−D異性体である請求項19に記載の医薬組成物。
- 化合物の少なくとも95重量%がβ−D異性体である請求項19に記載の医薬組成物。
- ウイルスがHCVである請求項19に記載の医薬組成物。
- 5’−水酸基が5’−ORで置換されており、Rがリン酸;安定化リン酸プロドラッグ;アシル;アルキル;アルキルもしくはアリールアルキルスルホニル(メタンスルホニルを含む)を含むスルホン酸エステル;フェニル基が場合により置換されていてもよいベンジル;脂質;アミノ酸;炭水化物;ペブチド;コレステロール;又はin vivo投与した場合にRが独立してHもしくはリン酸である化合物を提供することができる他の医薬的に許容可能な脱離基である式I又はIIの化合物。
- 5’−水酸基が5’−ORで置換されており、Rがリン酸;安定化リン酸プロドラッグ;アシル;アルキル;アルキルもしくはアリールアルキルスルホニル(メタンスルホニルを含む)を含むスルホン酸エステル;フェニル基が場合により置換されていてもよいベンジル;脂質;アミノ酸;炭水化物;ペブチド;コレステロール;又はin vivo投与した場合にRが独立してHもしくはリン酸である化合物を提供することができる他の医薬的に許容可能な脱離基である式I又はIIの化合物を医薬的に許容可能なキャリヤー中に含む医薬組成物。
- 医薬的に許容可能なキャリヤー中に含まれる、5’−水酸基が5’−ORで置換されており、Rが水素;リン酸;安定化リン酸プロドラッグ;アシル;アルキル;アルキルもしくはアリールアルキルスルホニル(メタンスルホニルを含む)を含むスルホン酸エステル;フェニル基が場合により置換されていてもよいベンジル;脂質;アミノ酸;炭水化物;ペブチド;コレステロール;又はin vivo投与した場合にRが独立してHもしくはリン酸である化合物を提供することができる他の医薬的に許容可能な脱離基である式I又はIIの化合物を含むRNA依存性RNAポリメラーゼウイルスに感染した宿主を治療するための医薬組成物。
- ウイルスがフラビウイルス科ウイルスである請求項39に記載の医薬組成物。
- フラビウイルス科ウイルスがC型肝炎ウイルスである請求項39又は40に記載の医薬組成物。
- 宿主がヒトである請求項39、40又は41に記載の医薬組成物。
- 医薬的に許容可能な塩が塩酸塩である請求項43に記載の使用。
- 医薬的に許容可能な塩が二塩酸塩である請求項43に記載の使用。
- 更に化合物を医薬的に許容可能なキャリヤー、希釈剤又は賦形剤に担持して投与することを含む請求項43に記載の使用。
- 化合物を第2の抗ウイルス剤と併用して製造する請求項43に記載の使用。
- 第2の抗ウイルス剤がインターフェロン、リバビリン、インターロイキン、NS3プロテアーゼ阻害剤、システインプロテアーゼ阻害剤、チアゾリジン誘導体、チアゾリジン、ベンズアニリド、フェナントレンキノン、ヘリカーゼ阻害剤、ポリメラーゼ阻害剤、ヌクレオチド類似体、グリオトキシン、セルレニン、アンチセンスホスホロチオエートオリゴデオキシヌクレオチド、IRES依存的翻訳の阻害剤、及びリボザイムから構成される群から選択される請求項47に記載の使用。
- 第2の抗ウイルス剤がインターフェロンである請求項47に記載の使用。
- 第2の抗ウイルス剤がペグ化インターフェロンα2a、インターフェロンαcon−1、天然インターフェロン、アルブフェロン、インターフェロンβ−1a、ωインターフェロン、インターフェロンα、インターフェロンγ、インターフェロンτ、インターフェロンδ及びインターフェロンγ−1bから構成される群から選択される請求項47に記載の使用。
- 第2の抗ウイルス剤がインターフェロンα2である請求項47に記載の使用。
- 宿主がヒトである請求項47に記載の使用。
- 化合物が用量単位の形態である請求項47に記載の使用。
- 用量単位が10〜500mgの化合物を含有する請求項43に記載の使用。
- 前記用量単位が錠剤又はカプセル剤である請求項43に記載の使用。
- 医薬的に許容可能なキャリヤーが経口送達に適している請求項43に記載の使用。
- 化合物を実質的に純粋形態で投与する請求項43に記載の使用。
- 化合物の少なくとも90重量%がβ−D異性体である請求項43に記載の使用。
- 化合物の少なくとも95重量%がβ−D異性体である請求項43に記載の使用。
- ウイルスがHCVである請求項43に記載の使用。
- 医薬的に許容可能な塩が塩酸塩である請求項61に記載の化合物。
- 医薬的に許容可能な塩が二塩酸塩である請求項61に記載の化合物。
- 医薬的に許容可能なキャリヤー、希釈剤又は賦形剤を更に含有する請求項61に記載の化合物。
- 第2の抗ウイルス剤を更に含有する請求項61に記載の化合物。
- 第2の抗ウイルス剤がインターフェロン、リバビリン、インターロイキン、NS3プロテアーゼ阻害剤、システインプロテアーゼ阻害剤、チアゾリジン誘導体、チアゾリジン、ベンズアニリド、フェナントレンキノン、ヘリカーゼ阻害剤、ポリメラーゼ阻害剤、ヌクレオチド類似体、グリオトキシン、セルレニン、アンチセンスホスホロチオエートオリゴデオキシヌクレオチド、IRES依存的翻訳の阻害剤、及びリボザイムから構成される群から選択される請求項65に記載の化合物。
- 第2の抗ウイルス剤がインターフェロンである請求項65に記載の化合物。
- 第2の抗ウイルス剤がペグ化インターフェロンα2a、インターフェロンαcon−1、天然インターフェロン、アルブフェロン、インターフェロンβ−1a、ωインターフェロン、インターフェロンα、インターフェロンγ、インターフェロンτ、インターフェロンδ及びインターフェロンγ−1bから構成される群から選択される請求項65に記載の化合物。
- 第2の抗ウイルス剤がインターフェロンα2である請求項65に記載の化合物。
- 宿主がヒトである請求項65に記載の化合物。
- 化合物が用量単位の形態である請求項65に記載の化合物。
- 用量単位が10〜500mgの化合物を含有する請求項61に記載の化合物。
- 前記用量単位が錠剤又はカプセル剤である請求項72に記載の化合物。
- 医薬的に許容可能なキャリヤーが経口送達に適している請求項61に記載の化合物。
- 化合物を実質的に純粋形態で投与する請求項61に記載の化合物。
- 化合物の少なくとも90重量%がβ−D異性体である請求項61に記載の化合物。
- 化合物の少なくとも95重量%がβ−D異性体である請求項61に記載の化合物。
- ウイルスがHCVである請求項61に記載の化合物。
- 医薬的に許容可能な塩がトシル酸塩、メタンスルホン酸塩、酢酸塩、クエン酸塩、マロン酸塩、酒石酸塩、琥珀酸塩、安息香酸塩、アスコルビン酸塩、α−ケトグルタル酸塩、及びα−グリセロリン酸塩、ギ酸塩、フマル酸塩、プロピオン酸塩、グリコール酸塩、乳酸塩、ピルビン酸塩、蓚酸塩、マレイン酸塩、サリチル酸塩、硫酸塩、スルホン酸塩、硝酸塩、重炭酸塩、臭素酸水素酸塩、臭化水素酸塩、ヨウ化水素酸塩、炭酸塩、及びリン酸塩から選択される請求項1又は61に記載の化合物。
- 医薬的に許容可能な塩がトシル酸塩、メタンスルホン酸塩、酢酸塩、クエン酸塩、マロン酸塩、酒石酸塩、琥珀酸塩、安息香酸塩、アスコルビン酸塩、α−ケトグルタル酸塩、及びα−グリセロリン酸塩、ギ酸塩、フマル酸塩、プロピオン酸塩、グリコール酸塩、乳酸塩、ピルビン酸塩、蓚酸塩、マレイン酸塩、サリチル酸塩、硫酸塩、スルホン酸塩、硝酸塩、重炭酸塩、臭素酸水素酸塩、臭化水素酸塩、ヨウ化水素酸塩、炭酸塩、及びリン酸塩から選択される請求項4に記載の組成物。
- 医薬的に許容可能な塩がトシル酸塩、メタンスルホン酸塩、酢酸塩、クエン酸塩、マロン酸塩、酒石酸塩、琥珀酸塩、安息香酸塩、アスコルビン酸塩、α−ケトグルタル酸塩、及びα−グリセロリン酸塩、ギ酸塩、フマル酸塩、プロピオン酸塩、グリコール酸塩、乳酸塩、ピルビン酸塩、蓚酸塩、マレイン酸塩、サリチル酸塩、硫酸塩、スルホン酸塩、硝酸塩、重炭酸塩、臭素酸水素酸塩、臭化水素酸塩、ヨウ化水素酸塩、炭酸塩、及びリン酸塩から選択される請求項19に記載の医薬組成物。
- 医薬的に許容可能な塩がトシル酸塩、メタンスルホン酸塩、酢酸塩、クエン酸塩、マロン酸塩、酒石酸塩、琥珀酸塩、安息香酸塩、アスコルビン酸塩、α−ケトグルタル酸塩、及びα−グリセロリン酸塩、ギ酸塩、フマル酸塩、プロピオン酸塩、グリコール酸塩、乳酸塩、ピルビン酸塩、蓚酸塩、マレイン酸塩、サリチル酸塩、硫酸塩、スルホン酸塩、硝酸塩、重炭酸塩、臭素酸水素酸塩、臭化水素酸塩、ヨウ化水素酸塩、炭酸塩、及びリン酸塩から選択される請求項42に記載の使用。
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US39235102P | 2002-06-28 | 2002-06-28 | |
US46619403P | 2003-04-28 | 2003-04-28 | |
US47094903P | 2003-05-14 | 2003-05-14 | |
PCT/US2003/020431 WO2004002422A2 (en) | 2002-06-28 | 2003-06-27 | 2’-c-methyl-3’-o-l-valine ester ribofuranosyl cytidine for treatment of flaviviridae infections |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2005533824A JP2005533824A (ja) | 2005-11-10 |
JP2005533824A5 true JP2005533824A5 (ja) | 2006-08-17 |
Family
ID=30003834
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2004518041A Pending JP2005533824A (ja) | 2002-06-28 | 2003-06-27 | フラビウイルス科感染の治療のための2’−c−メチル−3’−o−l−バリンエステルリボフラノシルシチジン |
Country Status (16)
Country | Link |
---|---|
US (9) | US7456155B2 (ja) |
EP (1) | EP1536804A4 (ja) |
JP (1) | JP2005533824A (ja) |
KR (1) | KR20050035194A (ja) |
CN (1) | CN1678326A (ja) |
AP (1) | AP2005003213A0 (ja) |
AU (1) | AU2003248748A1 (ja) |
BR (1) | BR0312278A (ja) |
CA (1) | CA2489552A1 (ja) |
LU (1) | LU92513I2 (ja) |
MA (1) | MA27374A1 (ja) |
MX (1) | MXPA04012802A (ja) |
NO (1) | NO20050490L (ja) |
PL (1) | PL374781A1 (ja) |
RS (1) | RS113904A (ja) |
WO (1) | WO2004002422A2 (ja) |
Families Citing this family (186)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
MY164523A (en) | 2000-05-23 | 2017-12-29 | Univ Degli Studi Cagliari | Methods and compositions for treating hepatitis c virus |
CZ301182B6 (cs) * | 2000-05-26 | 2009-12-02 | Idenix (Cayman) Limited | Použití nukleosidových derivátu pro výrobu farmaceutických prostredku pro lécení infekcí vyvolaných flaviviry a pestiviry |
US6875751B2 (en) * | 2000-06-15 | 2005-04-05 | Idenix Pharmaceuticals, Inc. | 3′-prodrugs of 2′-deoxy-β-L-nucleosides |
US7608600B2 (en) * | 2002-06-28 | 2009-10-27 | Idenix Pharmaceuticals, Inc. | Modified 2′ and 3′-nucleoside prodrugs for treating Flaviviridae infections |
NZ537662A (en) * | 2002-06-28 | 2007-10-26 | Idenix Cayman Ltd | 2'-C-methyl-3'-O-L-valine ester ribofuranosyl cytidine for treatment of flaviviridae infections |
AU2003248748A1 (en) * | 2002-06-28 | 2004-01-19 | Idenix (Cayman) Limited | 2'-c-methyl-3'-o-l-valine ester ribofuranosyl cytidine for treatment of flaviviridae infections |
WO2004009020A2 (en) | 2002-07-24 | 2004-01-29 | Merck & Co., Inc. | Pyrrolopyrimidine thionucleoside analogs as antivirals |
US7094768B2 (en) * | 2002-09-30 | 2006-08-22 | Genelabs Technologies, Inc. | Nucleoside derivatives for treating hepatitis C virus infection |
PL376043A1 (en) * | 2002-09-30 | 2005-12-12 | Genelabs Technologies, Inc. | Nucleoside derivatives for treating hepatitis c virus infection |
BR0315806A (pt) | 2002-10-31 | 2005-09-13 | Metabasis Therapeutics Inc | Fosfato diésteres cìclicos de 1,3-propano-1-aril diós e seu uso na preparação de pró-drogas |
HUE033832T2 (en) * | 2002-11-15 | 2018-01-29 | Idenix Pharmaceuticals Llc | 2'-methyl nucleosides in combination with interferon and Flaviviridae mutation |
JP5116972B2 (ja) * | 2002-12-12 | 2013-01-09 | イデニクス(ケイマン)リミテツド | 2’−分枝ヌクレオシドの製造方法 |
MXPA05006865A (es) * | 2002-12-23 | 2005-12-12 | Idenix Cayman Ltd | Proceso para la produccion de profarmacos 3'-nucleosidos. |
EP1626692A4 (en) * | 2003-03-28 | 2008-12-10 | Pharmasset Inc | COMPOUNDS FOR TREATING FLAVIVIRUS INFECTIONS |
EP3521297B1 (en) | 2003-05-30 | 2021-12-22 | Gilead Pharmasset LLC | Modified fluorinated nucleoside analogues |
EP1658302B1 (en) * | 2003-07-25 | 2010-08-25 | IDENIX Pharmaceuticals, Inc. | Purine nucleoside analogues for treating diseases caused by flaviviridae including hepatitis c |
WO2005018330A1 (en) * | 2003-08-18 | 2005-03-03 | Pharmasset, Inc. | Dosing regimen for flaviviridae therapy |
GB0320638D0 (en) | 2003-09-03 | 2003-10-01 | Novartis Ag | Organic compounds |
GB0500020D0 (en) | 2005-01-04 | 2005-02-09 | Novartis Ag | Organic compounds |
US20050182252A1 (en) | 2004-02-13 | 2005-08-18 | Reddy K. R. | Novel 2'-C-methyl nucleoside derivatives |
EA013207B1 (ru) | 2004-02-20 | 2010-04-30 | Бёрингер Ингельхайм Интернациональ Гмбх | Ингибиторы вирусной полимеразы |
EP1729814A2 (en) * | 2004-04-01 | 2006-12-13 | Cardiome Pharma Corp. | Pegylated ion channel modulating compounds |
EP1758453B1 (en) | 2004-06-15 | 2014-07-16 | Merck Sharp & Dohme Corp. | C-purine nucleoside analogs as inhibitors of rna-dependent rna viral polymerase |
CA2571675A1 (en) * | 2004-06-23 | 2006-01-05 | Idenix (Cayman) Limited | 5-aza-7-deazapurine derivatives for treating infections with flaviviridae |
CN101023094B (zh) | 2004-07-21 | 2011-05-18 | 法莫赛特股份有限公司 | 烷基取代的2-脱氧-2-氟代-d-呋喃核糖基嘧啶和嘌呤及其衍生物的制备 |
WO2006016657A1 (ja) | 2004-08-11 | 2006-02-16 | Chugai Seiyaku Kabushiki Kaisha | Hcv感染症を治療または予防するための薬剤 |
RU2433124C2 (ru) | 2004-09-14 | 2011-11-10 | Фармассет, Инк. | Способ получения 2'-фтор-2'-алкилзамещенных или других замещенных рибофуранозилпиримидинов и пуринов и их производных |
KR20070073805A (ko) * | 2004-09-24 | 2007-07-10 | 이데닉스 (케이만) 리미티드 | 플라비바이러스, 페스티바이러스 및 헤파시바이러스를치료하기 위한 방법 및 조성물 |
RU2007128099A (ru) * | 2004-12-23 | 2009-01-27 | Новартис АГ (CH) | Композиции для лечения гепатита с |
US7524831B2 (en) | 2005-03-02 | 2009-04-28 | Schering Corporation | Treatments for Flaviviridae virus infection |
GT200600119A (es) * | 2005-03-24 | 2006-10-25 | Composiciones farmaceuticas | |
WO2006137953A1 (en) | 2005-04-01 | 2006-12-28 | The Regents Of The Univerisity Of California | Phosphono-pent-2-en-1-yl nucleosides and analogs |
WO2006130217A2 (en) * | 2005-04-01 | 2006-12-07 | The Regents Of The University Of California | Substituted phosphate esters of nucleoside phosphonates |
WO2006119061A2 (en) | 2005-05-02 | 2006-11-09 | Merck & Co., Inc. | Hcv ns3 protease inhibitors |
BRPI0613142A2 (pt) | 2005-06-17 | 2010-12-21 | Novartis Ag | uso de sangliferina em hcv |
TWI387603B (zh) | 2005-07-20 | 2013-03-01 | Merck Sharp & Dohme | Hcv ns3蛋白酶抑制劑 |
RU2008107972A (ru) | 2005-08-01 | 2009-09-10 | Мерк энд Ко., Инк. (US) | Макроциклические пептиды в качестве ингибиторов ns3-протеазы hcv |
US20070185063A1 (en) * | 2005-08-23 | 2007-08-09 | Idenix Pharmaceuticals, Inc. | Seven-membered ring nucleosides |
EP1931696B1 (en) * | 2005-09-30 | 2011-02-16 | Scynexis, Inc. | Arylalkyl and heteroarylalkyl derivatives of cyclosporine a for the treatment and prevention of viral infection |
WO2007041632A2 (en) * | 2005-09-30 | 2007-04-12 | Scynexis, Inc. | Methods and pharmaceutical compositions for the treatment and prevention of hepatitis c infection |
RU2422454C2 (ru) | 2005-12-09 | 2011-06-27 | Ф. Хоффманн-Ля Рош Аг | Антивирусные нуклеозиды |
US7781576B2 (en) * | 2005-12-23 | 2010-08-24 | Idenix Pharmaceuticals, Inc. | Process for preparing a synthetic intermediate for preparation of branched nucleosides |
US8895531B2 (en) | 2006-03-23 | 2014-11-25 | Rfs Pharma Llc | 2′-fluoronucleoside phosphonates as antiviral agents |
WO2007113159A1 (en) | 2006-04-04 | 2007-10-11 | F. Hoffmann-La Roche Ag | 3',5'-di-o-acylated nucleosides for hcv treatment |
JP5167244B2 (ja) | 2006-04-11 | 2013-03-21 | ノバルティス アーゲー | Hcv/hiv阻害剤およびそれらの使用 |
GB0609492D0 (en) | 2006-05-15 | 2006-06-21 | Angeletti P Ist Richerche Bio | Therapeutic agents |
CN101489580A (zh) * | 2006-05-16 | 2009-07-22 | 财团法人东京都医学研究机构 | 治疗或预防hcv感染症的药物组合物 |
US8058260B2 (en) * | 2006-05-22 | 2011-11-15 | Xenoport, Inc. | 2′-C-methyl-ribofuranosyl cytidine prodrugs, pharmaceutical compositions and uses thereof |
GB0612423D0 (en) | 2006-06-23 | 2006-08-02 | Angeletti P Ist Richerche Bio | Therapeutic agents |
WO2008024763A2 (en) * | 2006-08-25 | 2008-02-28 | Wyeth | Identification and characterization of hcv replicon variants with reduced susceptibility to hcv-796, and methods related thereto |
US20080161324A1 (en) * | 2006-09-14 | 2008-07-03 | Johansen Lisa M | Compositions and methods for treatment of viral diseases |
ES2358853T3 (es) * | 2006-10-10 | 2011-05-16 | Medivir Ab | Inhibidor nucleosídico de vhc. |
JP5252459B2 (ja) * | 2006-10-10 | 2013-07-31 | ギリアド ファーマセット エルエルシー | リボフラノシルピリミジンヌクレオシドの調製 |
US8309540B2 (en) | 2006-10-24 | 2012-11-13 | Merck Sharp & Dohme Corp. | HCV NS3 protease inhibitors |
AU2007309546A1 (en) | 2006-10-24 | 2008-05-02 | Istituto Di Ricerche Di Biologia Molecolare P. Angeletti S.P.A. | HCV NS3 protease inhibitors |
US8138164B2 (en) | 2006-10-24 | 2012-03-20 | Merck Sharp & Dohme Corp. | HCV NS3 protease inhibitors |
WO2008057208A2 (en) | 2006-10-27 | 2008-05-15 | Merck & Co., Inc. | Hcv ns3 protease inhibitors |
WO2008057209A1 (en) | 2006-10-27 | 2008-05-15 | Merck & Co., Inc. | Hcv ns3 protease inhibitors |
KR101165936B1 (ko) | 2006-11-09 | 2012-07-19 | 에프. 호프만-라 로슈 아게 | 티아졸 및 옥사졸-치환된 아릴아마이드 |
US8501933B2 (en) | 2006-11-09 | 2013-08-06 | Roche Palo Alto Llc | Thiazole and oxazole-substituted arylamides as P2X3 and P2X2/3 antagonists |
US7576057B2 (en) | 2006-11-20 | 2009-08-18 | Scynexis, Inc. | Cyclic peptides |
AU2007335962B2 (en) | 2006-12-20 | 2012-09-06 | Istituto Di Ricerche Di Biologia Molecolare P. Angeletti Spa | Antiviral indoles |
GB0625345D0 (en) | 2006-12-20 | 2007-01-31 | Angeletti P Ist Richerche Bio | Therapeutic compounds |
GB0625349D0 (en) | 2006-12-20 | 2007-01-31 | Angeletti P Ist Richerche Bio | Therapeutic compounds |
US7951789B2 (en) | 2006-12-28 | 2011-05-31 | Idenix Pharmaceuticals, Inc. | Compounds and pharmaceutical compositions for the treatment of viral infections |
AU2007342367B2 (en) | 2007-01-05 | 2012-12-06 | Istituto Di Ricerche Di Biologia Molecolare P. Angeletti S.P.A. | Nucleoside aryl phosphoramidates for the treatment of RNA-dependent RNA viral infection |
US7964580B2 (en) | 2007-03-30 | 2011-06-21 | Pharmasset, Inc. | Nucleoside phosphoramidate prodrugs |
GB0709791D0 (en) * | 2007-05-22 | 2007-06-27 | Angeletti P Ist Richerche Bio | Antiviral agents |
CA2693537C (en) | 2007-07-17 | 2013-06-25 | Istituto Di Ricerche Di Biologia Molecolare P. Angeletti Spa | Macrocyclic indole derivatives for the treatment of hepatitis c infections |
CA2699891C (en) | 2007-07-19 | 2013-10-22 | Nigel Liverton | Macrocyclic compounds as antiviral agents |
US8227431B2 (en) * | 2008-03-17 | 2012-07-24 | Hetero Drugs Limited | Nucleoside derivatives |
TW200946541A (en) | 2008-03-27 | 2009-11-16 | Idenix Pharmaceuticals Inc | Solid forms of an anti-HIV phosphoindole compound |
US8461107B2 (en) | 2008-04-28 | 2013-06-11 | Merck Sharp & Dohme Corp. | HCV NS3 protease inhibitors |
CA2724523A1 (en) * | 2008-06-06 | 2010-01-07 | Scynexis, Inc. | Novel macrocyclic peptides |
US20090306033A1 (en) * | 2008-06-06 | 2009-12-10 | Keqiang Li | Novel cyclic peptides |
US8173621B2 (en) | 2008-06-11 | 2012-05-08 | Gilead Pharmasset Llc | Nucleoside cyclicphosphates |
KR20110065440A (ko) * | 2008-07-02 | 2011-06-15 | 아이데닉스 파마슈티칼스, 인코포레이티드 | 바이러스 감염의 치료를 위한 화합물 및 제약 조성물 |
DK2540350T3 (da) | 2008-07-22 | 2014-08-04 | Merck Sharp & Dohme | Kombinationer af en makrocyklisk quinoxalinforbindelse, hvilken er enhcv-ns3-protease-inhibitor med andre hcv-midler |
EP2332953A1 (en) | 2008-09-05 | 2011-06-15 | Kotobuki Pharmaceutical Co., Ltd. | Substituted amine derivative and medicinal composition comprising same as the active ingredient |
WO2010061881A1 (ja) | 2008-11-26 | 2010-06-03 | 中外製薬株式会社 | C型肝炎ウイルスの働きを阻害するオリゴリボヌクレオチドまたはペプチド核酸 |
KR20110104074A (ko) | 2008-12-23 | 2011-09-21 | 파마셋 인코포레이티드 | 퓨린 뉴클레오시드의 합성 |
CL2009002208A1 (es) | 2008-12-23 | 2010-10-29 | Gilead Pharmasset Llc | Un compuesto (2s)-2-((((2r,3r,4r,5r)-5-(2-amino-6-etoxi-9h-purin-9-il)-4-fluoro-3-hidroxi-4-metiltetrahidrofuran-2-il)metoxi)(hidroxi)fosforilamino)propanoico, inhibidores de la replicacion de arn viral; composicion farmaceutica; y su uso en el tratamiento de infeccion por hepatitis c, virus del nilo occidental, entre otras. |
SG172359A1 (en) | 2008-12-23 | 2011-07-28 | Pharmasset Inc | Nucleoside phosphoramidates |
AU2009334790B2 (en) * | 2008-12-31 | 2016-09-08 | Scynexis, Inc. | Derivatives of cyclosporin A |
WO2010082050A1 (en) | 2009-01-16 | 2010-07-22 | Istituto Di Ricerche Di Biologia Molecolare P. Angeletti S.P.A. | Macrocyclic and 7-aminoalkyl-substituted benzoxazocines for treatment of hepatitis c infections |
GB0900914D0 (en) | 2009-01-20 | 2009-03-04 | Angeletti P Ist Richerche Bio | Antiviral agents |
JP5690286B2 (ja) | 2009-03-04 | 2015-03-25 | イデニク プハルマセウティカルス,インコーポレイテッド | ホスホチオフェン及びホスホチアゾールhcvポリメラーゼ阻害剤 |
US8512690B2 (en) | 2009-04-10 | 2013-08-20 | Novartis Ag | Derivatised proline containing peptide compounds as protease inhibitors |
US20110182850A1 (en) | 2009-04-10 | 2011-07-28 | Trixi Brandl | Organic compounds and their uses |
US20100310656A1 (en) * | 2009-04-27 | 2010-12-09 | Immunitor USA, Inc. | Immunotherapy and prevention of autoimmune hepatitis |
US20100297079A1 (en) * | 2009-05-20 | 2010-11-25 | Chimerix, Inc. | Compounds, compositions and methods for treating viral infection |
TWI583692B (zh) | 2009-05-20 | 2017-05-21 | 基利法瑪席特有限責任公司 | 核苷磷醯胺 |
US8618076B2 (en) | 2009-05-20 | 2013-12-31 | Gilead Pharmasset Llc | Nucleoside phosphoramidates |
US9676797B2 (en) | 2015-09-02 | 2017-06-13 | Abbvie Inc. | Anti-viral compounds |
SG177308A1 (en) * | 2009-06-22 | 2012-02-28 | Hoffmann La Roche | Novel biphenyl and phenyl-pyridine amides |
CN102438989B (zh) * | 2009-06-22 | 2015-05-27 | 霍夫曼-拉罗奇有限公司 | 噁唑酮和吡咯烷酮取代的芳基酰胺 |
SG177301A1 (en) * | 2009-06-22 | 2012-02-28 | Hoffmann La Roche | Novel indole, indazole and benzimidazole arylamides as p2x3 and/or p2x2/3 antagonists |
EP2467144A1 (en) * | 2009-07-24 | 2012-06-27 | ViroLogik GmbH | Combination of proteasome inhibitors and anti-hepatitis medication for treating hepatitis |
EP2459582B1 (en) | 2009-07-30 | 2015-05-27 | Merck Sharp & Dohme Corp. | Hepatitis c virus ns3 protease inhibitors |
WO2011017389A1 (en) | 2009-08-05 | 2011-02-10 | Idenix Pharmaceuticals, Inc. | Macrocyclic serine protease inhibitors useful against viral infections, particularly hcv |
CA2780044A1 (en) | 2009-11-14 | 2011-05-19 | F. Hoffmann-La Roche Ag | Biomarkers for predicting rapid response to hcv treatment |
MX2012005601A (es) * | 2009-11-16 | 2012-08-01 | Univ Georgia | Nucleosidos carboxiclicos de 2'-fluoro-6'-metileno y metodos para tratar infecciones virales. |
WO2011063076A1 (en) | 2009-11-19 | 2011-05-26 | Itherx Pharmaceuticals, Inc. | Methods of treating hepatitis c virus with oxoacetamide compounds |
SG181104A1 (en) | 2009-12-02 | 2012-07-30 | Hoffmann La Roche | Biomarkers for predicting sustained response to hcv treatment |
JP2013514982A (ja) | 2009-12-18 | 2013-05-02 | イデニク プハルマセウティカルス,インコーポレイテッド | 5,5−縮合アリーレン又はヘテロアリーレンc型肝炎ウイルス阻害剤 |
PL3290428T3 (pl) | 2010-03-31 | 2022-02-07 | Gilead Pharmasset Llc | Tabletka zawierająca krystaliczny (S)-2-(((S)-(((2R,3R,4R,5R)-5-(2,4-diokso-3,4-dihydropirymidyn-1(2H)-ylo)-4-fluoro-3-hydroksy-4-metylotetrahydrofuran-2-ylo)metoksy)(fenoksy)fosforylo)amino)propanian izopropylu |
KR101715981B1 (ko) | 2010-03-31 | 2017-03-13 | 길리애드 파마셋 엘엘씨 | 뉴클레오사이드 포스포르아미데이트 |
US8680071B2 (en) | 2010-04-01 | 2014-03-25 | Idenix Pharmaceuticals, Inc. | Compounds and pharmaceutical compositions for the treatment of viral infections |
CA2812962C (en) | 2010-09-22 | 2020-03-31 | Alios Biopharma, Inc. | Azido nucleosides and nucleotide analogs |
US8871737B2 (en) | 2010-09-22 | 2014-10-28 | Alios Biopharma, Inc. | Substituted nucleotide analogs |
BR112013008510A2 (pt) | 2010-10-08 | 2016-07-05 | Novartis Ag | vitamina e formulações de inibidores de sulfamida ns3 |
AR084044A1 (es) | 2010-11-30 | 2013-04-17 | Pharmasset Inc | Compuestos 2’-espiro-nucleosidos |
WO2012080050A1 (en) | 2010-12-14 | 2012-06-21 | F. Hoffmann-La Roche Ag | Solid forms of a phenoxybenzenesulfonyl compound |
US9353100B2 (en) | 2011-02-10 | 2016-05-31 | Idenix Pharmaceuticals Llc | Macrocyclic serine protease inhibitors, pharmaceutical compositions thereof, and their use for treating HCV infections |
US20120252721A1 (en) | 2011-03-31 | 2012-10-04 | Idenix Pharmaceuticals, Inc. | Methods for treating drug-resistant hepatitis c virus infection with a 5,5-fused arylene or heteroarylene hepatitis c virus inhibitor |
CN103842369A (zh) | 2011-03-31 | 2014-06-04 | 埃迪尼克斯医药公司 | 用于治疗病毒感染的化合物和药物组合物 |
CN102775458B (zh) * | 2011-05-09 | 2015-11-25 | 中国人民解放军军事医学科学院毒物药物研究所 | β-D-(2’R)-2’-脱氧—2’-氟-2’-C-甲基胞苷衍生物的制备及用途 |
US9403863B2 (en) | 2011-09-12 | 2016-08-02 | Idenix Pharmaceuticals Llc | Substituted carbonyloxymethylphosphoramidate compounds and pharmaceutical compositions for the treatment of viral infections |
CA2847892A1 (en) | 2011-09-12 | 2013-03-21 | Idenix Pharmaceuticals, Inc. | Compounds and pharmaceutical compositions for the treatment of viral infections |
MD4589C1 (ro) | 2011-09-16 | 2019-03-31 | Gilead Pharmasset Llc | Compoziţie farmaceutică cu conţinut de sofosbuvir şi utilizarea acesteia în tratamentul hepatitei virale C |
US8507460B2 (en) | 2011-10-14 | 2013-08-13 | Idenix Pharmaceuticals, Inc. | Substituted 3′,5′-cyclic phosphates of purine nucleotide compounds and pharmaceutical compositions for the treatment of viral infections |
WO2013074386A2 (en) | 2011-11-15 | 2013-05-23 | Merck Sharp & Dohme Corp. | Hcv ns3 protease inhibitors |
US8889159B2 (en) | 2011-11-29 | 2014-11-18 | Gilead Pharmasset Llc | Compositions and methods for treating hepatitis C virus |
US9089574B2 (en) | 2011-11-30 | 2015-07-28 | Emory University | Antiviral JAK inhibitors useful in treating or preventing retroviral and other viral infections |
EP2794630A4 (en) | 2011-12-22 | 2015-04-01 | Alios Biopharma Inc | SUBSTITUTED PHOSPHORTHIOAT NUCLEOTIDE ANALOGUE |
DK2794627T3 (en) | 2011-12-22 | 2019-01-14 | Alios Biopharma Inc | SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALOGUES THEREOF |
US20130217644A1 (en) | 2012-02-13 | 2013-08-22 | Idenix Pharmaceuticals, Inc. | Pharmaceutical Compositions of 2'-C-Methyl-Guanosine, 5'-[2[(3-Hydroxy-2,2-Dimethyl-1-Oxopropyl)Thio]Ethyl N-(Phenylmethyl)Phosphoramidate] |
BR112014019897A8 (pt) | 2012-02-14 | 2017-07-11 | Univ Georgia | Espiro[2.4]heptanos para tratamento de infecções por flaviviridae |
USRE48171E1 (en) | 2012-03-21 | 2020-08-25 | Janssen Biopharma, Inc. | Substituted nucleosides, nucleotides and analogs thereof |
US9441007B2 (en) | 2012-03-21 | 2016-09-13 | Alios Biopharma, Inc. | Substituted nucleosides, nucleotides and analogs thereof |
US8916538B2 (en) | 2012-03-21 | 2014-12-23 | Vertex Pharmaceuticals Incorporated | Solid forms of a thiophosphoramidate nucleotide prodrug |
NZ630805A (en) | 2012-03-22 | 2016-01-29 | Alios Biopharma Inc | Pharmaceutical combinations comprising a thionucleotide analog |
WO2013177188A1 (en) | 2012-05-22 | 2013-11-28 | Idenix Pharmaceuticals, Inc. | 3',5'-cyclic phosphoramidate prodrugs for hcv infection |
MD20140134A2 (ro) | 2012-05-22 | 2015-04-30 | Idenix Pharmaceuticals, Inc. | Compuşi ai D-aminoacizilor pentru tratamentul bolilor hepatice |
WO2013177195A1 (en) | 2012-05-22 | 2013-11-28 | Idenix Pharmaceuticals, Inc. | 3',5'-cyclic phosphate prodrugs for hcv infection |
CN104395330B (zh) | 2012-05-25 | 2018-03-13 | 爱尔兰詹森科学公司 | 尿嘧啶基螺氧杂环丁烷核苷 |
US9192621B2 (en) | 2012-09-27 | 2015-11-24 | Idenix Pharmaceuticals Llc | Esters and malonates of SATE prodrugs |
CN104936970A (zh) | 2012-10-08 | 2015-09-23 | 埃迪尼克斯医药公司 | 用于hcv感染的2′-氯核苷类似物 |
WO2014063019A1 (en) | 2012-10-19 | 2014-04-24 | Idenix Pharmaceuticals, Inc. | Dinucleotide compounds for hcv infection |
EP2909222B1 (en) | 2012-10-22 | 2021-05-26 | Idenix Pharmaceuticals LLC | 2',4'-bridged nucleosides for hcv infection |
CN104955458A (zh) * | 2012-11-07 | 2015-09-30 | Z·索 | 取代的吉西他滨芳基酰胺类似物和使用所述类似物的治疗方法 |
EP2920195A1 (en) | 2012-11-14 | 2015-09-23 | IDENIX Pharmaceuticals, Inc. | D-alanine ester of rp-nucleoside analog |
US20140140952A1 (en) | 2012-11-14 | 2014-05-22 | Idenix Pharmaceuticals, Inc. | D-Alanine Ester of Sp-Nucleoside Analog |
WO2014099941A1 (en) | 2012-12-19 | 2014-06-26 | Idenix Pharmaceuticals, Inc. | 4'-fluoro nucleosides for the treatment of hcv |
MY172166A (en) | 2013-01-31 | 2019-11-15 | Gilead Pharmasset Llc | Combination formulation of two antiviral compounds |
US10034893B2 (en) * | 2013-02-01 | 2018-07-31 | Enanta Pharmaceuticals, Inc. | 5, 6-D2 uridine nucleoside/tide derivatives |
WO2014121418A1 (en) | 2013-02-07 | 2014-08-14 | Merck Sharp & Dohme Corp. | Tetracyclic heterocycle compounds and methods of use thereof for the treatment of hepatitis c |
WO2014121417A1 (en) | 2013-02-07 | 2014-08-14 | Merck Sharp & Dohme Corp. | Tetracyclic heterocycle compounds and methods of use thereof for the treatment of hepatitis c |
EP2970358B1 (en) | 2013-03-04 | 2021-06-30 | Idenix Pharmaceuticals LLC | 3'-deoxy nucleosides for the treatment of hcv |
US9339541B2 (en) | 2013-03-04 | 2016-05-17 | Merck Sharp & Dohme Corp. | Thiophosphate nucleosides for the treatment of HCV |
US20140271547A1 (en) | 2013-03-13 | 2014-09-18 | Idenix Pharmaceuticals, Inc. | Amino acid phosphoramidate pronucleotides of 2'-cyano, azido and amino nucleosides for the treatment of hcv |
US9187515B2 (en) | 2013-04-01 | 2015-11-17 | Idenix Pharmaceuticals Llc | 2′,4′-fluoro nucleosides for the treatment of HCV |
WO2014169280A2 (en) | 2013-04-12 | 2014-10-16 | Achillion Pharmaceuticals, Inc. | Deuterated nucleoside prodrugs useful for treating hcv |
WO2014197578A1 (en) | 2013-06-05 | 2014-12-11 | Idenix Pharmaceuticals, Inc. | 1',4'-thio nucleosides for the treatment of hcv |
US20150037282A1 (en) | 2013-08-01 | 2015-02-05 | Idenix Pharmaceuticals, Inc. | D-amino acid phosphoramidate pronucleotides of halogeno pyrimidine compounds for liver disease |
PL3650014T3 (pl) | 2013-08-27 | 2022-01-31 | Gilead Pharmasset Llc | Preparat złożony dwóch związków przeciwwirusowych |
US20160229866A1 (en) | 2013-09-20 | 2016-08-11 | Idenix Pharmaceuticals Inc. | Hepatitis c virus inhibitors |
WO2015061683A1 (en) | 2013-10-25 | 2015-04-30 | Idenix Pharmaceuticals, Inc. | D-amino acid phosphoramidate and d-alanine thiophosphoramidate pronucleotides of nucleoside compounds useful for the treatment of hcv |
US20160271162A1 (en) | 2013-11-01 | 2016-09-22 | Idenix Pharmacueticals, Llc | D-alanine phosphoramide pronucleotides of 2'-methyl 2'-fluro guanosine nucleoside compounds for the treatment of hcv |
EP3074399A1 (en) | 2013-11-27 | 2016-10-05 | Idenix Pharmaceuticals LLC | 2'-dichloro and 2'-fluoro-2'-chloro nucleoside analogues for hcv infection |
US10683321B2 (en) | 2013-12-18 | 2020-06-16 | Idenix Pharmaceuticals Llc | 4′-or nucleosides for the treatment of HCV |
CN114404427A (zh) | 2014-02-13 | 2022-04-29 | 配体药物公司 | 前药化合物及其用途 |
EP3113763A1 (en) | 2014-03-05 | 2017-01-11 | Idenix Pharmaceuticals LLC | Solid prodrug forms of 2'-chloro-2'-methyl uridine for hcv |
WO2015134561A1 (en) | 2014-03-05 | 2015-09-11 | Idenix Pharmaceuticals, Inc. | Pharmaceutical compositions comprising a 5,5-fused heteroarylene flaviviridae inhibitor and their use for treating or preventing flaviviridae infection |
US20170066779A1 (en) | 2014-03-05 | 2017-03-09 | Idenix Pharmaceuticals Llc | Solid forms of a flaviviridae virus inhibitor compound and salts thereof |
WO2015161137A1 (en) | 2014-04-16 | 2015-10-22 | Idenix Pharmaceuticals, Inc. | 3'-substituted methyl or alkynyl nucleosides for the treatment of hcv |
CN106459133B (zh) * | 2014-06-10 | 2019-12-06 | 安捷伦科技有限公司 | 用于“z核苷酸”的保护基团及其方法 |
EP3164136A4 (en) | 2014-07-02 | 2018-04-04 | Ligand Pharmaceuticals, Inc. | Prodrug compounds and uses therof |
WO2016033164A1 (en) | 2014-08-26 | 2016-03-03 | Enanta Pharmaceuticals, Inc. | Nucleoside and nucleotide derivatives |
US9718851B2 (en) | 2014-11-06 | 2017-08-01 | Enanta Pharmaceuticals, Inc. | Deuterated nucleoside/tide derivatives |
US9732110B2 (en) | 2014-12-05 | 2017-08-15 | Enanta Pharmaceuticals, Inc. | Nucleoside and nucleotide derivatives |
AU2016229966B2 (en) | 2015-03-06 | 2018-09-27 | Atea Pharmaceuticals, Inc. | Beta-D-2'-deoxy-2'alpha-fluoro-2'-beta-C-substituted-2-modified-N6-substituted purine nucleotides for HCV treatment |
CN106146588A (zh) * | 2015-03-26 | 2016-11-23 | 常州制药厂有限公司 | 一种索非布韦的制备方法 |
CN109562113A (zh) | 2016-05-10 | 2019-04-02 | C4医药公司 | 用于靶蛋白降解的螺环降解决定子体 |
CN109641874A (zh) | 2016-05-10 | 2019-04-16 | C4医药公司 | 用于靶蛋白降解的c3-碳连接的戊二酰亚胺降解决定子体 |
WO2017197055A1 (en) | 2016-05-10 | 2017-11-16 | C4 Therapeutics, Inc. | Heterocyclic degronimers for target protein degradation |
US10711029B2 (en) | 2016-07-14 | 2020-07-14 | Atea Pharmaceuticals, Inc. | Beta-d-2′-deoxy-2′-alpha-fluoro-2′-beta-c-substituted-4′fluoro-n6-substituted-6-amino-2-substituted purine nucleotides for the treatment of hepatitis c virus infection |
ES2907874T3 (es) | 2016-09-07 | 2022-04-26 | Atea Pharmaceuticals Inc | Nucleótidos de purina 2'-sustituidos-N6-sustituidos para el tratamiento de virus de ARN |
CN106432388B (zh) * | 2016-09-14 | 2018-11-30 | 江苏福瑞生物医药有限公司 | (2’r) -2’-脱氧-2’-氟- 2’-甲基脲苷的制备方法 |
CN115477679A (zh) | 2017-02-01 | 2022-12-16 | 阿堤亚制药公司 | 用于治疗丙型肝炎病毒的核苷酸半硫酸盐 |
US10435429B2 (en) | 2017-10-03 | 2019-10-08 | Nucorion Pharmaceuticals, Inc. | 5-fluorouridine monophosphate cyclic triester compounds |
EP3737676B1 (en) | 2018-01-09 | 2024-03-06 | Ligand Pharmaceuticals, Inc. | Acetal compounds and therapeutic uses thereof |
US11427550B2 (en) | 2018-01-19 | 2022-08-30 | Nucorion Pharmaceuticals, Inc. | 5-fluorouracil compounds |
JP2021521118A (ja) | 2018-04-10 | 2021-08-26 | アテア ファーマシューティカルズ, インコーポレイテッド | 肝硬変を伴うhcv感染患者の治療 |
US10874687B1 (en) | 2020-02-27 | 2020-12-29 | Atea Pharmaceuticals, Inc. | Highly active compounds against COVID-19 |
CN115605492A (zh) | 2020-04-21 | 2023-01-13 | 配体制药股份有限公司(Us) | 核苷酸前药化合物 |
Family Cites Families (180)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6458772B1 (en) | 1909-10-07 | 2002-10-01 | Medivir Ab | Prodrugs |
US3074929A (en) | 1955-08-11 | 1963-01-22 | Burroughs Wellcome Co | Glycosides of 6-mercaptopurine |
GB924246A (en) | 1958-12-23 | 1963-04-24 | Wellcome Found | Purine derivatives and their preparation |
US3116282A (en) | 1960-04-27 | 1963-12-31 | Upjohn Co | Pyrimidine nucleosides and process |
GB984877A (en) | 1962-08-16 | 1965-03-03 | Waldhof Zellstoff Fab | Improvements in and relating to 6-halonucleosides |
FR1498856A (ja) | 1965-11-15 | 1968-01-10 | ||
CH490395A (de) | 1965-11-15 | 1970-05-15 | Merck & Co Inc | Verfahren zur Herstellung neuartiger Nukleoside |
FR1521076A (fr) | 1966-05-02 | 1968-04-12 | Merck & Co Inc | Nucléosides de purines substituées |
DE1695411A1 (de) | 1966-05-02 | 1971-04-15 | Merck & Co Inc | Substituierte Purin-Nucleoside und Verfahren zu deren Herstellung |
US3480613A (en) | 1967-07-03 | 1969-11-25 | Merck & Co Inc | 2-c or 3-c-alkylribofuranosyl - 1-substituted compounds and the nucleosides thereof |
DE2122991C2 (de) | 1971-05-04 | 1982-06-09 | Schering Ag, 1000 Berlin Und 4619 Bergkamen | Verfahren zur Herstellung von Cytosin- und 6-Azacytosinnucleosiden |
US3798209A (en) * | 1971-06-01 | 1974-03-19 | Icn Pharmaceuticals | 1,2,4-triazole nucleosides |
USRE29835E (en) | 1971-06-01 | 1978-11-14 | Icn Pharmaceuticals | 1,2,4-Triazole nucleosides |
US4022889A (en) | 1974-05-20 | 1977-05-10 | The Upjohn Company | Therapeutic compositions of antibiotic U-44,590 and methods for using the same |
DE2508312A1 (de) | 1975-02-24 | 1976-09-02 | Schering Ag | Neues verfahren zur herstellung von nucleosiden |
US4058602A (en) | 1976-08-09 | 1977-11-15 | The United States Of America As Represented By The Department Of Health, Education And Welfare | Synthesis, structure, and antitumor activity of 5,6-dihydro-5-azacytidine |
DE2757365A1 (de) | 1977-12-20 | 1979-06-21 | Schering Ag | Neues verfahren zur herstellung von nucleosiden |
DE2852721A1 (de) | 1978-12-06 | 1980-06-26 | Basf Ag | Verfahren zur reindarstellung von kaliumribonat und ribonolacton |
US4239753A (en) | 1978-12-12 | 1980-12-16 | The Upjohn Company | Composition of matter and process |
US4522811A (en) * | 1982-07-08 | 1985-06-11 | Syntex (U.S.A.) Inc. | Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides |
US4540707A (en) * | 1983-01-28 | 1985-09-10 | Bayer Aktiengesellschaft | Nafazatrom as a lipoxygenase inhibitor |
FR2562543B1 (fr) | 1984-04-10 | 1987-09-25 | Elf Aquitaine | Nouveaux phosphonites cycliques, leur preparation et applications |
NL8403224A (nl) * | 1984-10-24 | 1986-05-16 | Oce Andeno Bv | Dioxafosforinanen, de bereiding ervan en de toepassing voor het splitsen van optisch actieve verbindingen. |
JPS61204193A (ja) | 1985-03-05 | 1986-09-10 | Takeda Chem Ind Ltd | シトシンヌクレオシド類の製造法 |
US6448392B1 (en) | 1985-03-06 | 2002-09-10 | Chimerix, Inc. | Lipid derivatives of antiviral nucleosides: liposomal incorporation and method of use |
US5223263A (en) | 1988-07-07 | 1993-06-29 | Vical, Inc. | Liponucleotide-containing liposomes |
US4605659A (en) * | 1985-04-30 | 1986-08-12 | Syntex (U.S.A.) Inc. | Purinyl or pyrimidinyl substituted hydroxycyclopentane compounds useful as antivirals |
US4754026A (en) * | 1985-06-04 | 1988-06-28 | Takeda Chemical Industries, Ltd. | Conversion of uracil derivatives to cytosine derivatives |
DE3714473A1 (de) | 1987-04-30 | 1988-11-10 | Basf Ag | Kontinuierliches verfahren zur epimerisierung von zuckern, insbesondere von d-arabinose zu d-ribose |
GB8719367D0 (en) | 1987-08-15 | 1987-09-23 | Wellcome Found | Therapeutic compounds |
US5246924A (en) | 1987-09-03 | 1993-09-21 | Sloan-Kettering Institute For Cancer Research | Method for treating hepatitis B virus infections using 1-(2'-deoxy-2'-fluoro-beta-D-arabinofuranosyl)-5-ethyluracil |
JPH03501253A (ja) | 1987-09-22 | 1991-03-22 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | エイズ(aids)治療を目的とするリポソームによるヌクレオシド類似物質 |
US4880784A (en) | 1987-12-21 | 1989-11-14 | Brigham Young University | Antiviral methods utilizing ribofuranosylthiazolo[4,5-d]pyrimdine derivatives |
US4852740A (en) * | 1988-03-11 | 1989-08-01 | Information Packaging Corp. | Holder for flat objects such as computer disks |
US5122517A (en) | 1988-06-10 | 1992-06-16 | Regents Of The University Of Minnesota | Antiviral combination comprising nucleoside analogs |
GB8815265D0 (en) * | 1988-06-27 | 1988-08-03 | Wellcome Found | Therapeutic nucleosides |
US6599887B2 (en) | 1988-07-07 | 2003-07-29 | Chimerix, Inc. | Methods of treating viral infections using antiviral liponucleotides |
US6252060B1 (en) | 1988-07-07 | 2001-06-26 | Nexstar Pharmaceuticals, Inc. | Antiviral liponucleosides: treatment of hepatitis B |
SE8802687D0 (sv) | 1988-07-20 | 1988-07-20 | Astra Ab | Nucleoside derivatives |
US5744600A (en) | 1988-11-14 | 1998-04-28 | Institute Of Organic Chemistry And Biochemistry Of The Academy Of Sciences Of The Czech Republic | Phosphonomethoxy carbocyclic nucleosides and nucleotides |
US5616702A (en) | 1988-11-15 | 1997-04-01 | Merrell Pharmaceuticals Inc. | 2-'-ethenylidene cytidine, uridine and guanosine derivatives |
US5705363A (en) * | 1989-03-02 | 1998-01-06 | The Women's Research Institute | Recombinant production of human interferon τ polypeptides and nucleic acids |
US5411947A (en) | 1989-06-28 | 1995-05-02 | Vestar, Inc. | Method of converting a drug to an orally available form by covalently bonding a lipid to the drug |
US5194654A (en) * | 1989-11-22 | 1993-03-16 | Vical, Inc. | Lipid derivatives of phosphonoacids for liposomal incorporation and method of use |
US5463092A (en) | 1989-11-22 | 1995-10-31 | Vestar, Inc. | Lipid derivatives of phosphonacids for liposomal incorporation and method of use |
US6060592A (en) * | 1990-01-11 | 2000-05-09 | Isis Pharmaceuticals, Inc. | Pyrimidine nucleoside compounds and oligonucleoside compounds containing same |
US5200514A (en) * | 1990-01-19 | 1993-04-06 | University Of Georgia Research Foundation, Inc. | Synthesis of 2'-deoxypyrimidine nucleosides |
US5204466A (en) | 1990-02-01 | 1993-04-20 | Emory University | Method and compositions for the synthesis of bch-189 and related compounds |
WO1991016920A1 (en) | 1990-05-07 | 1991-11-14 | Vical, Inc. | Lipid prodrugs of salicylate and nonsteroidal anti-inflammatory drugs |
FR2662165B1 (fr) | 1990-05-18 | 1992-09-11 | Univ Paris Curie | Derives nucleosidiques branches, leur procede de preparation et leur utilisation a titre de medicament. |
EP0531452A4 (en) | 1990-05-29 | 1993-06-09 | Vical, Inc. | Synthesis of glycerol di- and triphosphate derivatives |
CA2083961A1 (en) | 1990-05-29 | 1991-11-30 | Henk Van Den Bosch | Synthesis of glycerol di- and triphosphate derivatives |
DE69115694T2 (de) | 1990-06-13 | 1996-10-17 | Arnold Newton Mass. Glazier | Phosphorylierte prodrugs |
US5627165A (en) | 1990-06-13 | 1997-05-06 | Drug Innovation & Design, Inc. | Phosphorous prodrugs and therapeutic delivery systems using same |
US5372808A (en) | 1990-10-17 | 1994-12-13 | Amgen Inc. | Methods and compositions for the treatment of diseases with consensus interferon while reducing side effect |
US5256641A (en) | 1990-11-01 | 1993-10-26 | State Of Oregon | Covalent polar lipid-peptide conjugates for immunological targeting |
US5543390A (en) * | 1990-11-01 | 1996-08-06 | State Of Oregon, Acting By And Through The Oregon State Board Of Higher Education, Acting For And On Behalf Of The Oregon Health Sciences University | Covalent microparticle-drug conjugates for biological targeting |
US5827819A (en) | 1990-11-01 | 1998-10-27 | Oregon Health Sciences University | Covalent polar lipid conjugates with neurologically active compounds for targeting |
US5149794A (en) | 1990-11-01 | 1992-09-22 | State Of Oregon | Covalent lipid-drug conjugates for drug targeting |
US5543389A (en) * | 1990-11-01 | 1996-08-06 | State Of Oregon, Acting By And Through The Oregon State Board Of Higher Education On Behalf Of The Oregon Health Sciences University, A Non Profit Organization | Covalent polar lipid-peptide conjugates for use in salves |
IL100502A (en) | 1991-01-03 | 1995-12-08 | Iaf Biochem Int | PHARMACEUTICAL PREPARATIONS CONTAINING CIS-4-AMINO-1-) 2-HYDROXIMETHIL-1,3-OXETYOLEN-5-IL (- |
JPH04266880A (ja) | 1991-02-22 | 1992-09-22 | Japan Tobacco Inc | 3 −dpa− ラクトンの製造方法 |
US5157027A (en) | 1991-05-13 | 1992-10-20 | E. R. Squibb & Sons, Inc. | Bisphosphonate squalene synthetase inhibitors and method |
CA2112803A1 (en) | 1991-07-12 | 1993-01-21 | Karl Y. Hostetler | Antiviral liponucleosides: treatment of hepatitis b |
JPH0525152A (ja) | 1991-07-22 | 1993-02-02 | Japan Tobacco Inc | 3−dpa−ラクトンの製造法 |
US5554728A (en) | 1991-07-23 | 1996-09-10 | Nexstar Pharmaceuticals, Inc. | Lipid conjugates of therapeutic peptides and protease inhibitors |
TW224053B (ja) | 1991-09-13 | 1994-05-21 | Paul B Chretien | |
US5676942A (en) | 1992-02-10 | 1997-10-14 | Interferon Sciences, Inc. | Composition containing human alpha interferon species proteins and method for use thereof |
US5401861A (en) | 1992-06-22 | 1995-03-28 | Eli Lilly And Company | Low temperature process for preparing alpha-anomer enriched 2-deoxy-2,2-difluoro-D-ribofuranosyl sulfonates |
US5821357A (en) | 1992-06-22 | 1998-10-13 | Eli Lilly And Company | Stereoselective glycosylation process for preparing 2'-deoxy-2',2'-difluoropurine and triazole nucleosides |
US5371210A (en) | 1992-06-22 | 1994-12-06 | Eli Lilly And Company | Stereoselective fusion glycosylation process for preparing 2'-deoxy-2',2'-difluoronucleosides and 2'-deoxy-2'-fluoronucleosides |
US5256797A (en) | 1992-06-22 | 1993-10-26 | Eli Lilly And Company | Process for separating 2-deoxy-2,2-difluoro-D-ribofuranosyl alkylsulfonate anomers |
US5606048A (en) * | 1992-06-22 | 1997-02-25 | Eli Lilly And Company | Stereoselective glycosylation process for preparing 2'-Deoxy-2', 2'-difluoronucleosides and 2'-deoxy-2'-fluoronucleosides |
DE4224737A1 (de) | 1992-07-27 | 1994-02-03 | Herbert Prof Dr Schott | Neue Cytosinnucleosidanaloga, Verfahren zu ihrer Herstellung und ihre Verwendung |
IL106840A (en) | 1992-09-01 | 1998-09-24 | Lilly Co Eli | Process for basic anatomization of pentopornosyl nucleosides |
GB9226729D0 (en) | 1992-12-22 | 1993-02-17 | Wellcome Found | Therapeutic combination |
GB9307043D0 (en) | 1993-04-05 | 1993-05-26 | Norsk Hydro As | Chemical compounds |
WO1994026273A1 (en) | 1993-05-12 | 1994-11-24 | Hostetler Karl Y | Acyclovir derivatives for topical use |
US6156501A (en) | 1993-10-26 | 2000-12-05 | Affymetrix, Inc. | Arrays of modified nucleic acid probes and methods of use |
US5587362A (en) | 1994-01-28 | 1996-12-24 | Univ. Of Ga Research Foundation | L-nucleosides |
US5696277A (en) | 1994-11-15 | 1997-12-09 | Karl Y. Hostetler | Antiviral prodrugs |
NZ297100A (en) | 1994-12-13 | 1997-10-24 | Akira Matsuda | 3'-substituted nucleoside derivatives; medicaments |
DE19513330A1 (de) | 1995-04-03 | 1996-10-10 | Schering Ag | Neues Verfahren zur Herstellung von Nucleosiden |
US5977061A (en) | 1995-04-21 | 1999-11-02 | Institute Of Organic Chemistry And Biochemistry Of The Academy Of Sciences Of The Czech Republic | N6 - substituted nucleotide analagues and their use |
CA2231442A1 (en) * | 1995-09-07 | 1997-03-13 | University Of Georgia Research Foundation, Inc. | Therapeutic azide compounds |
US5908621A (en) | 1995-11-02 | 1999-06-01 | Schering Corporation | Polyethylene glycol modified interferon therapy |
US5980884A (en) | 1996-02-05 | 1999-11-09 | Amgen, Inc. | Methods for retreatment of patients afflicted with Hepatitis C using consensus interferon |
GB9609932D0 (en) * | 1996-05-13 | 1996-07-17 | Hoffmann La Roche | Use of IL-12 and IFN alpha for the treatment of infectious diseases |
RU2188828C2 (ru) * | 1996-10-16 | 2002-09-10 | Ай-Си-Эн Фармасьютикалз, Инк. | Моноциклические l-нуклеозиды, их аналоги и применения |
NZ507848A (en) | 1996-10-28 | 2005-01-28 | Univ Washington | Method of increasing the mutation rate of a virus in a non-human by administering an RNA nucleoside analogue to a virally infected cell |
US6248878B1 (en) | 1996-12-24 | 2001-06-19 | Ribozyme Pharmaceuticals, Inc. | Nucleoside analogs |
US6172046B1 (en) | 1997-09-21 | 2001-01-09 | Schering Corporation | Combination therapy for eradicating detectable HCV-RNA in patients having chronic Hepatitis C infection |
ES2162393T3 (es) | 1997-09-21 | 2001-12-16 | Schering Corp | Terapia de combinacion para erradicar el hcv-rna detectable en pacientes con infeccion de hepatitis c cronica. |
US6472373B1 (en) | 1997-09-21 | 2002-10-29 | Schering Corporation | Combination therapy for eradicating detectable HCV-RNA in antiviral treatment naive patients having chronic hepatitis C infection |
KR100263166B1 (ko) * | 1997-09-30 | 2000-08-01 | 윤종용 | 촬영신호 전송방법 및 전송장치 |
DK1058686T3 (da) * | 1998-02-25 | 2007-03-05 | Univ Emory | 2'-fluornukleosider |
US6312662B1 (en) | 1998-03-06 | 2001-11-06 | Metabasis Therapeutics, Inc. | Prodrugs phosphorus-containing compounds |
KR100389853B1 (ko) | 1998-03-06 | 2003-08-19 | 삼성전자주식회사 | 카타로그정보의기록및재생방법 |
WO1999045016A2 (en) | 1998-03-06 | 1999-09-10 | Metabasis Therapeutics, Inc. | Novel prodrugs for phosphorus-containing compounds |
ES2172288T3 (es) | 1998-05-15 | 2002-09-16 | Schering Corp | Terapia de combinacion que comprende ribavirina e interferon alfa en pacientes que no han sido sometidos a tratamiento antiviral y que tienen infeccion cronica de hepatitis c. |
US6833361B2 (en) | 1998-05-26 | 2004-12-21 | Ribapharm, Inc. | Nucleosides having bicyclic sugar moiety |
ATE307597T1 (de) | 1998-06-08 | 2005-11-15 | Hoffmann La Roche | Verwendung von peg-ifn-alpha und ribavirin zur behandlung chronischer hepatitis c |
US6444652B1 (en) | 1998-08-10 | 2002-09-03 | Novirio Pharmaceuticals Limited | β-L-2'-deoxy-nucleosides for the treatment of hepatitis B |
CN100387237C (zh) | 1998-08-10 | 2008-05-14 | 艾丹尼克斯(开曼)有限公司 | 用于治疗乙型肝炎的β-L-2'-脱氧-核苷 |
JP2002525295A (ja) * | 1998-09-25 | 2002-08-13 | バイロファーマ・インコーポレイテッド | ウイルス感染および関連疾患の治療または予防法 |
US6277830B1 (en) | 1998-10-16 | 2001-08-21 | Schering Corporation | 5′-amino acid esters of ribavirin and the use of same to treat hepatitis C with interferon |
CA2252144A1 (en) | 1998-10-16 | 2000-04-16 | University Of Alberta | Dual action anticancer prodrugs |
FR2784892B1 (fr) | 1998-10-23 | 2001-04-06 | Smith & Nephew Kinetec Sa | Attelle de mobilisation passive repliable pour membre inferieur |
AU774720B2 (en) | 1998-11-05 | 2004-07-08 | Centre National De La Recherche Scientifique | Nucleosides with anti-hepatitis B virus activity |
WO2000037110A2 (en) | 1998-12-18 | 2000-06-29 | Schering Corporation | Ribavirin-pegylated interferon alfa induction hcv combination therapy |
EP1155017B1 (en) * | 1999-02-22 | 2003-01-15 | Shire Biochem Inc. | [1,8] naphthyridine derivatives having antiviral activity |
DE60030263T2 (de) | 1999-03-05 | 2007-08-30 | Metabasis Therapeutics, Inc., La Jolla | Neue phosphor enthaltende medikamentenvorläuferverbindungen |
US6831069B2 (en) | 1999-08-27 | 2004-12-14 | Ribapharm Inc. | Pyrrolo[2,3-d]pyrimidine nucleoside analogs |
JP4979866B2 (ja) * | 1999-09-08 | 2012-07-18 | リガンド・ファーマシューティカルズ・インコーポレイテッド | 肝臓に特異的なドラッグデリバリーのためのプロドラッグ |
AU1262001A (en) | 1999-11-04 | 2001-05-14 | Biochem Pharma Inc. | Method for the treatment or prevention of flaviviridae viral infection using nucleoside analogues |
JP2003519154A (ja) | 1999-12-22 | 2003-06-17 | メタバシス・セラピューティクス・インコーポレイテッド | 新規なビスアミダートホスホネートプロドラッグ |
US6455508B1 (en) | 2000-02-15 | 2002-09-24 | Kanda S. Ramasamy | Methods for treating diseases with tirazole and pyrrolo-pyrimidine ribofuranosyl nucleosides |
US6495677B1 (en) | 2000-02-15 | 2002-12-17 | Kanda S. Ramasamy | Nucleoside compounds |
US7056895B2 (en) * | 2000-02-15 | 2006-06-06 | Valeant Pharmaceuticals International | Tirazole nucleoside analogs and methods for using same |
SK11922002A3 (sk) | 2000-02-18 | 2003-06-03 | Shire Biochem Inc. | Použitie analógov nukleozidov na liečenie alebo prevenciu infekcií spôsobených flavivírusom |
DE60136620D1 (de) | 2000-04-13 | 2009-01-02 | Pharmasset Inc | 3 oder 2 hydroxymethyl substituierte nucleoside derivate und ihre verwendung zur behandlung von virusinfektionen |
AU2001255495A1 (en) | 2000-04-20 | 2001-11-07 | Schering Corporation | Ribavirin-interferon alfa combination therapy for eradicating detectable hcv-rnain patients having chronic hepatitis c infection |
MY164523A (en) * | 2000-05-23 | 2017-12-29 | Univ Degli Studi Cagliari | Methods and compositions for treating hepatitis c virus |
CZ301182B6 (cs) * | 2000-05-26 | 2009-12-02 | Idenix (Cayman) Limited | Použití nukleosidových derivátu pro výrobu farmaceutických prostredku pro lécení infekcí vyvolaných flaviviry a pestiviry |
IL153078A0 (en) | 2000-05-26 | 2003-06-24 | Idenix Cayman Ltd | Methods for treating hepatitis delta virus infection with beta-l-2' deoxy nucleosides |
US6787526B1 (en) | 2000-05-26 | 2004-09-07 | Idenix Pharmaceuticals, Inc. | Methods of treating hepatitis delta virus infection with β-L-2′-deoxy-nucleosides |
US6875751B2 (en) * | 2000-06-15 | 2005-04-05 | Idenix Pharmaceuticals, Inc. | 3′-prodrugs of 2′-deoxy-β-L-nucleosides |
MY141594A (en) * | 2000-06-15 | 2010-05-14 | Novirio Pharmaceuticals Ltd | 3'-PRODRUGS OF 2'-DEOXY-ß-L-NUCLEOSIDES |
US6815542B2 (en) | 2000-06-16 | 2004-11-09 | Ribapharm, Inc. | Nucleoside compounds and uses thereof |
US6403584B1 (en) * | 2000-06-22 | 2002-06-11 | Merck & Co., Inc. | Substituted nipecotyl derivatives as inhibitors of cell adhesion |
US20030008841A1 (en) | 2000-08-30 | 2003-01-09 | Rene Devos | Anti-HCV nucleoside derivatives |
CA2318667C (en) * | 2000-09-11 | 2004-02-24 | Fci Canada Inc. | Monolithic semiconductor photo-coupler incorporating an optical fiber alignment groove |
NZ575481A (en) | 2000-10-18 | 2010-10-29 | Pharmasset Inc | Simultaneous quantification of nucleic acids in diseased cells |
PT1411954E (pt) | 2000-10-18 | 2011-03-16 | Pharmasset Inc | Nucleosídeos modificados para o tratamento de infecções virais e proliferação celular anormal |
CA2425522A1 (en) | 2000-10-18 | 2002-04-25 | Schering Corporation | Ribavirin-pegylated interferon alfa hcv combination therapy |
KR20030081343A (ko) | 2000-12-15 | 2003-10-17 | 파마셋, 리미티드 | 플라비비리다에 감염 치료용 항바이러스제 |
US7105499B2 (en) * | 2001-01-22 | 2006-09-12 | Merck & Co., Inc. | Nucleoside derivatives as inhibitors of RNA-dependent RNA viral polymerase |
ES2532836T3 (es) | 2001-01-22 | 2015-04-01 | Merck Sharp & Dohme Corp. | Derivados de nucleósidos como inhibidores de la ARN polimerasa viral dependiente de ARN |
US6669805B2 (en) * | 2001-02-16 | 2003-12-30 | International Business Machines Corporation | Drill stack formation |
IL157478A0 (en) | 2001-03-01 | 2004-03-28 | Pharmasset Ltd | Method for the synthesis of 2', 3'-didehydronucleosides |
GB0112617D0 (en) | 2001-05-23 | 2001-07-18 | Hoffmann La Roche | Antiviral nucleoside derivatives |
GB0114286D0 (en) | 2001-06-12 | 2001-08-01 | Hoffmann La Roche | Nucleoside Derivatives |
AU2002322325A1 (en) | 2001-06-22 | 2003-01-08 | Emory University | Beta-2'-or 3'-halonucleosides |
WO2003024461A1 (en) | 2001-09-20 | 2003-03-27 | Schering Corporation | Hcv combination therapy |
WO2003026675A1 (en) | 2001-09-28 | 2003-04-03 | Idenix (Cayman) Limited | Methods and compositions for treating flaviviruses and pestiviruses using 4'-modified nucleoside |
CN100560073C (zh) | 2001-12-14 | 2009-11-18 | 法玛塞特公司 | 用于治疗病毒感染的n4-酰基胞嘧啶核苷 |
US6965066B1 (en) | 2002-01-16 | 2005-11-15 | Actodyne General, Inc. | Elongated string support for a stringed musical instrument |
US20040010717A1 (en) * | 2002-01-29 | 2004-01-15 | Intertainer Asia Pte Ltd. | Apparatus and method for preventing digital media piracy |
NZ534811A (en) | 2002-02-14 | 2007-07-27 | Pharmasset Inc | Modified fluorinated nucleoside analogues |
CA2477741A1 (en) * | 2002-02-28 | 2003-09-04 | Biota, Inc. | Nucleotide mimics and their prodrugs |
US7247621B2 (en) * | 2002-04-30 | 2007-07-24 | Valeant Research & Development | Antiviral phosphonate compounds and methods therefor |
WO2003093290A2 (en) | 2002-05-06 | 2003-11-13 | Genelabs Technologies, Inc. | Nucleoside derivatives for treating hepatitis c virus infection |
CA2488484A1 (en) | 2002-06-27 | 2004-01-08 | Merck & Co., Inc. | Nucleoside derivatives as inhibitors of rna-dependent rna viral polymerase |
AU2003248748A1 (en) | 2002-06-28 | 2004-01-19 | Idenix (Cayman) Limited | 2'-c-methyl-3'-o-l-valine ester ribofuranosyl cytidine for treatment of flaviviridae infections |
CA2490200C (en) * | 2002-06-28 | 2012-01-03 | Idenix (Cayman) Limited | 2' and 3'-nucleoside prodrugs for treating flaviviridae infections |
US20060264389A1 (en) | 2002-07-16 | 2006-11-23 | Balkrishen Bhat | Nucleoside derivatives as inhibitors of rna-dependent rna viral polymerase |
WO2004009020A2 (en) | 2002-07-24 | 2004-01-29 | Merck & Co., Inc. | Pyrrolopyrimidine thionucleoside analogs as antivirals |
US7094768B2 (en) * | 2002-09-30 | 2006-08-22 | Genelabs Technologies, Inc. | Nucleoside derivatives for treating hepatitis C virus infection |
PL376043A1 (en) | 2002-09-30 | 2005-12-12 | Genelabs Technologies, Inc. | Nucleoside derivatives for treating hepatitis c virus infection |
HUE033832T2 (en) * | 2002-11-15 | 2018-01-29 | Idenix Pharmaceuticals Llc | 2'-methyl nucleosides in combination with interferon and Flaviviridae mutation |
TWI332507B (en) | 2002-11-19 | 2010-11-01 | Hoffmann La Roche | Antiviral nucleoside derivatives |
JP5116972B2 (ja) | 2002-12-12 | 2013-01-09 | イデニクス(ケイマン)リミテツド | 2’−分枝ヌクレオシドの製造方法 |
WO2004084453A2 (en) | 2003-03-20 | 2004-09-30 | Microbiologica Quimica E Farmaceutica Ltd. | METHODS OF MANUFACTURE OF 2'-DEOXY-β-L-NUCLEOSIDES |
US20040259934A1 (en) | 2003-05-01 | 2004-12-23 | Olsen David B. | Inhibiting Coronaviridae viral replication and treating Coronaviridae viral infection with nucleoside compounds |
US20040229839A1 (en) | 2003-05-14 | 2004-11-18 | Biocryst Pharmaceuticals, Inc. | Substituted nucleosides, preparation thereof and use as inhibitors of RNA viral polymerases |
EP3521297B1 (en) * | 2003-05-30 | 2021-12-22 | Gilead Pharmasset LLC | Modified fluorinated nucleoside analogues |
WO2005000864A1 (en) | 2003-06-19 | 2005-01-06 | F. Hoffmann-La Roche Ag | Processes for preparing 4’azido nucleoside derivatives |
US7144868B2 (en) | 2003-10-27 | 2006-12-05 | Genelabs Technologies, Inc. | Nucleoside compounds for treating viral infections |
US20050137141A1 (en) * | 2003-10-24 | 2005-06-23 | John Hilfinger | Prodrug composition |
NZ546201A (en) | 2003-10-27 | 2009-05-31 | Genelabs Tech Inc | Nucleoside compounds for treating viral infections |
MXPA06004680A (es) * | 2003-10-27 | 2007-04-17 | Genelabs Tech Inc | Compuestos de nucleosido para el tratamiento de infecciones virales. |
CN101023094B (zh) | 2004-07-21 | 2011-05-18 | 法莫赛特股份有限公司 | 烷基取代的2-脱氧-2-氟代-d-呋喃核糖基嘧啶和嘌呤及其衍生物的制备 |
ATE543789T1 (de) | 2004-07-21 | 2012-02-15 | Pharmasset Inc | Herstellung von alkylsubstituierten 2-desoxy-2- fluor-d-ribofuranosylpyrimidinen und -purinen und derivaten davon |
WO2006021341A1 (en) * | 2004-08-23 | 2006-03-02 | F. Hoffmann-La Roche Ag | Antiviral 4’-azido-nucleosides |
US7544632B2 (en) * | 2004-09-22 | 2009-06-09 | Exxonmobil Research And Engineering Company | Bulk Ni-Mo-W catalysts made from precursors containing an organic agent |
WO2006121468A1 (en) | 2004-11-22 | 2006-11-16 | Genelabs Technologies, Inc. | 5-nitro-nucleoside compounds for treating viral infections |
KR20070102741A (ko) | 2005-02-09 | 2007-10-19 | 미게닉스 인코포레이티드 | 플라비비리대 감염증을 치료하거나 예방하기 위한 조성물및 방법 |
DE102005012681A1 (de) | 2005-03-18 | 2006-09-21 | Weber, Lutz, Dr. | Neue 1,5-Dihydro-pyrrol-2-one |
TW200720285A (en) | 2005-04-25 | 2007-06-01 | Genelabs Tech Inc | Nucleoside compounds for treating viral infections |
US7781576B2 (en) | 2005-12-23 | 2010-08-24 | Idenix Pharmaceuticals, Inc. | Process for preparing a synthetic intermediate for preparation of branched nucleosides |
-
2003
- 2003-06-27 AU AU2003248748A patent/AU2003248748A1/en not_active Abandoned
- 2003-06-27 US US10/607,909 patent/US7456155B2/en active Active
- 2003-06-27 JP JP2004518041A patent/JP2005533824A/ja active Pending
- 2003-06-27 RS YUP-1139/04A patent/RS113904A/sr unknown
- 2003-06-27 MX MXPA04012802A patent/MXPA04012802A/es not_active Application Discontinuation
- 2003-06-27 KR KR1020047021073A patent/KR20050035194A/ko not_active Application Discontinuation
- 2003-06-27 CA CA002489552A patent/CA2489552A1/en not_active Abandoned
- 2003-06-27 CN CNA03820701XA patent/CN1678326A/zh active Pending
- 2003-06-27 EP EP03762183A patent/EP1536804A4/en not_active Withdrawn
- 2003-06-27 BR BRPI0312278-6A patent/BR0312278A/pt not_active IP Right Cessation
- 2003-06-27 AP AP2005003213A patent/AP2005003213A0/xx unknown
- 2003-06-27 PL PL03374781A patent/PL374781A1/xx not_active Application Discontinuation
- 2003-06-27 US US10/609,298 patent/US7662798B2/en not_active Expired - Fee Related
- 2003-06-27 WO PCT/US2003/020431 patent/WO2004002422A2/en active Search and Examination
-
2004
- 2004-12-06 US US11/005,444 patent/US7625875B2/en not_active Expired - Fee Related
- 2004-12-06 US US11/005,440 patent/US20070060503A1/en not_active Abandoned
- 2004-12-06 US US11/005,446 patent/US20070060504A1/en not_active Abandoned
- 2004-12-06 US US11/005,466 patent/US20070060541A1/en not_active Abandoned
- 2004-12-06 US US11/005,472 patent/US20070060505A1/en not_active Abandoned
- 2004-12-06 US US11/005,471 patent/US20070042990A1/en not_active Abandoned
- 2004-12-06 US US11/005,442 patent/US20070037735A1/en not_active Abandoned
-
2005
- 2005-01-25 MA MA28070A patent/MA27374A1/fr unknown
- 2005-01-27 NO NO20050490A patent/NO20050490L/no not_active Application Discontinuation
-
2014
- 2014-08-07 LU LU92513C patent/LU92513I2/xx unknown
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2005533824A5 (ja) | ||
RU2011133741A (ru) | Модифицированные 2'- и 3'-нуклеозиды и их применение для получения лекарственного средства для лечения инфекций flaviviridae | |
JP2004533401A5 (ja) | ||
CA2490200A1 (en) | 2' and 3'-nucleoside prodrugs for treating flaviviridae infections | |
RU2006105640A (ru) | Аналоги пуриновых нуклеозидов для лечения flaviviridae, включая гепатит с | |
JP5539363B2 (ja) | インターフェロンおよびリバビリンとのhcvns3プロテアーゼ阻害剤の組合せ | |
JP2012502956A (ja) | Hcvの大環状阻害剤とヌクレオシドの相乗性組み合わせ剤 | |
JP2007501185A5 (ja) | ||
JP2010514768A5 (ja) | ||
CA2729168A1 (en) | Compounds and pharmaceutical compositions for the treatment of viral infections | |
IL201239A (en) | Phosphoramide Nucleuside Compounds | |
KR20070102741A (ko) | 플라비비리대 감염증을 치료하거나 예방하기 위한 조성물및 방법 | |
JP2012504126A5 (ja) | ||
JP2010539241A5 (ja) | ||
JP2005290015A (ja) | 抗ウイルス化合物 | |
JP2012519691A5 (ja) | ||
ES2662700T9 (es) | Componente de silibinina para el tratamiento de la hepatitis | |
JP2021521118A (ja) | 肝硬変を伴うhcv感染患者の治療 | |
JPWO2017155082A1 (ja) | 抗肝腫瘍ウイルス剤 | |
CZ20011130A3 (cs) | Sloučenina, farmaceutický prostředek a jejich použití pro ribavirin-interferon alfa kombinovanou terapii | |
CN102775458A (zh) | β-D-(2’R)-2’-脱氧—2’-氟-2’-C-甲基胞苷衍生物的制备及用途 | |
JP2006524227A5 (ja) | ||
CA2863645A1 (en) | Once daily treatment of hepatitis c with ribavirin and taribavirin | |
JP2002509154A5 (ja) | ||
ES2338642T3 (es) | Terapia de combinacion para tratar virus de la hepatitis b. |